AMS and Carbon-14 Radiolabelled Biologics
AMS and Carbon-14 Radiolabelled Biologics Services
Due to the high molecular weight of some biologics and macromolecules, the specific activity of the radiolabelled analog can often be too low for quantitation by traditional methods (LSC, QWBA, MARG). In these instances, Pharmaron is unique in providing Accelerator Mass Spectrometry (AMS) technology to quantify total radioactivity and metabolites in biological specimens with a significantly (more sensitive) lower level of quantitation (LLOQ). This can also help address similar limitations encountered with other bioanalytical techniques such as LC/MS-MS and immunoassays.
Pharmaron’s team offers radiolabelling of biologics with 14C combined with Accelerator Mass Spectrometry (AMS) analysis to provide pharmacokinetic (PK) and tissue disposition data in animal models.
Capabilities
Target Turnover Studies
Assessing target turnover can be critical to determining if that target is druggable. Some drug targets turn over too quickly to be a viable route or pathway to treating disease.
By labelling the target exogenously with 14C and reintroducing it into the desired species, AMS can help determine the metabolism and catabolism of the target in the endogenous pool. Most drug targets studied have been 14C radiolabelled proteins and cytokines.
AMS also has the sensitivity to quantify 14C radioactivity in expired air collected from both non-clinical and clinical studies.
Total [14C] by AMS and Bioanalysis of [14C] Parent Compound and Metabolites
- ADCs
- Oligonucleotides
- Fusion proteins
- Peptides
Analysis of Parent Compound, Metabolites and Total Radioactivity (TRA)
- Blood/plasma
- Urine
- Feces
- Bile
- CSF
- Kidney tissue
- Liver tissue
- Skin tissue
- Spleen tissue
- PBMCs
